A new study highlights the Cardio-Ankle Vascular Index (CAVI) as a powerful tool for predicting COPD progression and outcomes ...

The FDA approved mepolizumab (Nucala) for adults with inadequately controlled chronic obstructive pulmonary disease (COPD), ...

We have developed a new, multidimensional diagnostic schema for COPD that incorporates spirometry, symptoms, and imaging and ...

The schema newly classified 15.4% of persons without airflow obstruction as having COPD by minor diagnostic category, Surya P ...

COPD is a group of progressive lung diseases that includes emphysema and chronic bronchitis. Despite affecting an estimated 32 million people in the United States, as many as half are unaware they ...

Patients with COPD and type 2 inflammation receiving mepolizumab vs. placebo had decreased moderate and severe exacerbation ...

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of ...

Women with COPD, asthma, and OSA may go undiagnosed or without proper care because their symptomatology differs from the male ...

Eucalyptus oil was first used by Aboriginal Australians, who crushed the leaves for their antiseptic properties or steamed ...

The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

The Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for the add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD ...